FDA Approves Foundation Medicine’s FoundationOne CDx Comprehensive Genomic Profiling Test

FDA has approved the FoundationOne CDx (F1CDx) cancer biomarker assay concurrently with a decision from the Centers for Medicare & Medicaid Services (CMS) to provide insurance coverage for the next-generation sequencing (NGS)-based in vitro diagnostic (IVD) test.

FDA Approves Foundation Medicine’s FoundationOne CDx™, the First and Only Comprehensive Genomic Profiling Test for All Solid Tumors Incorporating Multiple Companion Diagnostics.

Read more about it here

Online Active Surveillance Virtual Support Group

Prostate Cancer International announces the development and official opening of its online Active Surveillance Virtual Support Group. This group will meet by webinar or conference call once a month, with the next webinar on Wednesday, December 6, at 2:00 pm Eastern Time (11:00 am Pacific). Registration is required to join.

For more information, click here

US Too Prostate Cancer Panel Discussion and Webcast on Advanced Prostate Cancer

US Too Prostate Cancer Panel Discussion and Webcast on Advanced Prostate Cancer

  • Presented by: Bayer
  • Sponsored by: Dendreon and Jannsen Oncology
  • In Kind Sponsor: Los Padres
  • Guest Speakers:
    • Dr. Edwin Morales – Urology Specialist, San Antonio
    • Dr. Michael Liss – Urologist, Urologic Oncologist, and Lead Prostate Cancer Researcher at UT Health, San Antonio
    • Dr. Vijay K. Gunuganti – Medical Oncologist at Texas Oncology
    • Moderator: Dr. Juan A. Reyna – Staff Physician at Audie L. Murphy Memorial VA Hospital; and Clinical Faculty at UT Health

Watch the recording here

Dr. Mark Scholz and Panel Discussion Video – El Camino Hospital

Dr. Mark Scholz participated in a tumor board session with a discussion of Prostate Cancer Cases at El Camino Hospital in November 2017.

Participants included:

  • Robert Sinha, MD, Medical Director of Radiation Oncology
  • Frank Lai, MD, Urological Oncologist/Robotic Surgeon, El Camino Hospital
  • Steven Kurtzman, MD, Radiation Oncologist, Director of Prostate Brachytherapy, El Camino Hospital
  • Shane Dormady, MD PhD, Medical Director of Oncology, El Camino Hospital
  • Mark Scholz, MD, Medical Oncology, Director of Prostate Cancer Specialists, Founder of Prostate Cancer Research Institute

View the recording of the event here

Event: Dr. Mark Scholz Participates in Discussion of Prostate Cancer Cases

Dr. Mark Scholz will participate in a tumor board session – Discussion of Prostate Cancer Cases. It will be an open seating event.

Date/Time:

Friday, November 10, 2017, 4:30-7:00 PM PST

Location:

El Camino Hospital, 2500 Grant Road, Mountain View, CA 94040

Conference Rooms E, F & G

Moderator:

  • Robert Sinha, MD, Medical Director of Radiation Oncology

Panelists:

  • Frank Lai, MD, Urological Oncologist/Robotic Surgeon, El Camino Hospital
  • Steven Kurtzman, MD, Radiation Oncologist, Director of Prostate Brachytherapy, El Camino Hospital
  • Shane Dormady, MD PhD, Medical Director of Oncology, El Camino Hospital
  • Mark Scholz, MD, Medical Oncology, Director of Prostate Cancer Specialists, Founder of Prostate Cancer Research Institute

Download the event flyer from here

Register for the event here

A Short Course in Prostate Cancer by Thomas J. Leih (eBook)

A Short Course in Prostate Cancer – eBook

The purpose of this short eBook is to provide men facing prostate cancer with a lot of up-to-date information in a compact format.

The information and opinions provided in this book are not specific medical advice for any individual. It  should not substitute for medical advice from a healthcare professional. The author is not a medical doctor. The reader is advised that any information or opinions expressed or implied in this book are those of a layman and should not be acted upon without the consent of a licensed physician. This book is not meant to be used, nor should it be used, to diagnose or treat any medical condition. For diagnosis or treatment of any medical problem, consult your own physician.

Download the pdf ebook here.

Patient Access Network (PAN) Foundation offers financial assistance for cancer patients

The Patient Access Network (PAN) Foundation offers cancer patients help with copay assistance, out-of-pocket costs, insurance premiums, and travel expenses.

Focus is largely under insured Medicare patients with income between 200%-400% of the federal poverty level, living in the US – grant of about $7500 a year for prostate cancer patients.

Read more on Prostatepedia here

Prostate Cancer Risk Assessment and the UCSF-CAPRA Score

Risk Assessment systems are not intended to replace individualized clinician-patient decision making, but rather to provide a straightforward instrument for facilitating disease risk classification in clinical decision making and in future research.

The classification developed by D’Amico and colleagues is one of the most widely used and is a good starting point for risk assessment. This system uses PSA level (blood test), Gleason grade (microscopic appearance of the cancer cells), and T stage (size of the tumor on rectal exam and/or ultrasound) to group men as low, intermediate, or high-risk.

Low-risk: PSA less than or equal to 10, Gleason score less than or equal to 6, and clinical stage T1-2a

Intermediate risk: PSA between 10 and 20, Gleason score 7, or clinical stage T2b

High-risk: PSA more than 20, Gleason score equal or larger than 8, or clinical stage T2c-3a

Limitations: Does not account for multiple risk factors

Read more and access the risk assessment calculator here on the UCSF site